Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity

  • J Med Chem. 2007 Nov 15;50(23):5543-6. doi: 10.1021/jm701079h.
Oscar M Moradei  1 ,  Tammy C Mallais ,  Sylvie Frechette ,  Isabelle Paquin ,  Pierre E Tessier ,  Silvana M Leit ,  Marielle Fournel ,  Claire Bonfils ,  Marie-Claude Trachy-Bourget ,  Jianhong Liu ,  Theresa P Yan ,  Ai-Hua Lu ,  Jubrail Rahil ,  James Wang ,  Sylvain Lefebvre ,  Zuomei Li ,  Arkadii F Vaisburg ,  Jeffrey M Besterman
Affiliations
  • 1. MethylGene Inc, 7220 Frederick-Banting, Montréal, QC H4S 2A1, Canada. [email protected]
PMID: 17941625 DOI: 10.1021/jm701079h
Abstract

Significant effort is being made to understand the role of HDAC isotypes in human Cancer and to develop antitumor agents with better therapeutic windows. A part of this endeavor was the exploration of the 14 A internal cavity adjacent to the enzyme catalytic site, which led to the design and synthesis of compound 4 with the unusual bis(aryl)-type pharmacophore. SAR studies around this lead resulted in optimization to potent, selective, nonhydroxamic acid HDAC inhibitors.

Products